Rigel Anticipates Full-Year Revenue of Approximately $275M-$290M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy RIGL?
Rigel anticipates full-year total revenue of approximately $275M-$290M, including net product sales of $255M-$265M, and positive net income for the full year. "2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data," said Raul Rodriguez, Rigel's president and CEO. "In 2026, we plan to continue to execute across all areas of the business - driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RIGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RIGL
Wall Street analysts forecast RIGL stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 34.620
Low
38.00
Averages
52.00
High
71.00
Current: 34.620
Low
38.00
Averages
52.00
High
71.00
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rigel Pharmaceuticals to Announce Q4 Earnings on March 3
- Earnings Announcement Schedule: Rigel Pharmaceuticals is set to release its Q4 2023 earnings on March 3 after market close, with consensus EPS estimated at $1.20 and revenue projected at $68.7 million, reflecting a 19.3% year-over-year growth, which will provide crucial insights into the company's financial health.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen four upward revisions and one downward adjustment, indicating increased analyst confidence in the company's profitability, while revenue estimates have also experienced three upward revisions and one downward, reflecting a positive market outlook for Rigel's future growth.
- Market Reaction Potential: As the earnings report approaches, investor interest in Rigel Pharmaceuticals is rising, particularly against the backdrop of its continued financial performance and potential catalysts in 2026, which could positively impact the stock price and further drive market interest in the company.
- Industry Analysis Perspective: Rigel Pharmaceuticals' short-term performance is supported by Seeking Alpha's Quant Rating, highlighting its attractiveness among small-cap stocks with high short interest, potentially drawing more investor attention to its future strategic developments.
See More
Rigel Pharmaceuticals Reports Strong 2025 Financial Results
- Revenue Growth: Rigel Pharmaceuticals reported total revenues of $69.8 million for Q4 2025, with net product sales reaching $65.4 million, reflecting a 41% increase year-over-year, indicating strong market demand in hematologic disorders and cancer treatments.
- Product Sales Performance: Net product sales for TAVALISSE, GAVRETO, and REZLIDHIA were $45.6 million, $10.2 million, and $9.6 million respectively, representing growth of 47%, 27%, and 29% compared to 2024, demonstrating increasing market acceptance of the company's product line.
- Significant Net Income Increase: Rigel achieved a net income of $268.1 million in Q4 2025, with earnings per share of $14.72, a substantial rise from $14.3 million and $0.81 in the same quarter of 2024, reflecting a marked improvement in the company's profitability.
- Optimistic 2026 Outlook: Rigel anticipates total revenues of approximately $275 to $290 million for 2026 and plans to advance its R289 program, showcasing the company's confidence and strategic positioning for future growth.
See More
Rigel Pharmaceuticals Q4 Earnings Exceed Expectations
- Strong Earnings Report: Rigel Pharmaceuticals reported a Q4 GAAP EPS of $13.54, surpassing expectations by $12.31, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenues of $69.8 million, reflecting a 21.2% year-over-year increase and exceeding market expectations by $1.1 million, indicating sustained competitiveness of its products in the market.
- Future Outlook: Rigel anticipates total revenues for 2026 to be between $275 million and $290 million, with net product sales projected at $255 million to $265 million and contract revenues at $20 million to $25 million, showcasing confidence in future growth.
- Positive Market Response: Rigel Pharmaceuticals presented its ongoing financial performance and future catalysts at the 44th Annual J.P. Morgan Healthcare Conference, further solidifying its market position in the biopharmaceutical sector.
See More
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Rigel Pharmaceuticals Appoints New Board Member
- New Board Member: Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of commercial and leadership experience in the biotechnology and pharmaceutical industries, which is expected to provide valuable insights for the company's strategic plans.
- Commercial Execution Expertise: Miller previously served as Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and held senior commercial roles at Vivus and Genentech, and his extensive experience will aid Rigel in achieving its goals of growing its drug portfolio and exploring potential in-licensing opportunities.
- Company Growth Outlook: Miller noted that Rigel has evolved into a profitable company with a strong commercial engine capable of funding a promising development pipeline, a significant advantage in the biotechnology space.
- Commitment to Patient Care: Miller expressed excitement about joining Rigel and is committed to focusing on opportunities to serve more patients with hematologic disorders and cancer, underscoring the company's dedication to improving patient lives.
See More
Rigel Pharmaceuticals Projects 2026 Revenue of $275 to $290 Million
- Strong Financial Performance: Rigel Pharmaceuticals anticipates total revenue for 2025 to reach approximately $275 to $290 million, reflecting robust commercial execution and expected positive net income, which will further solidify its financial foundation.
- Significant Clinical Advancements: Rigel's R289 drug has shown promising data in the Phase 1b trial for lower-risk myelodysplastic syndromes (MDS), marking a major milestone in clinical development that could pave the way for future market expansion.
- Robust Cash Flow: In 2025, Rigel successfully generated $77 million in cash, ensuring ample funding for existing and new clinical development programs, thereby enhancing its competitive position in the market.
- Investor Event Arrangement: CEO Raul Rodriguez will present an overview of the company at the J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to further enhance the company's visibility and credibility among investors.
See More
Rigel Pharmaceuticals to Announce Q4 Earnings on March 3
- Earnings Announcement Schedule: Rigel Pharmaceuticals is set to release its Q4 2023 earnings on March 3 after market close, with consensus EPS estimated at $1.20 and revenue projected at $68.7 million, reflecting a 19.3% year-over-year growth, which will provide crucial insights into the company's financial health.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen four upward revisions and one downward adjustment, indicating increased analyst confidence in the company's profitability, while revenue estimates have also experienced three upward revisions and one downward, reflecting a positive market outlook for Rigel's future growth.
- Market Reaction Potential: As the earnings report approaches, investor interest in Rigel Pharmaceuticals is rising, particularly against the backdrop of its continued financial performance and potential catalysts in 2026, which could positively impact the stock price and further drive market interest in the company.
- Industry Analysis Perspective: Rigel Pharmaceuticals' short-term performance is supported by Seeking Alpha's Quant Rating, highlighting its attractiveness among small-cap stocks with high short interest, potentially drawing more investor attention to its future strategic developments.
See More
Rigel Pharmaceuticals Reports Strong 2025 Financial Results
- Revenue Growth: Rigel Pharmaceuticals reported total revenues of $69.8 million for Q4 2025, with net product sales reaching $65.4 million, reflecting a 41% increase year-over-year, indicating strong market demand in hematologic disorders and cancer treatments.
- Product Sales Performance: Net product sales for TAVALISSE, GAVRETO, and REZLIDHIA were $45.6 million, $10.2 million, and $9.6 million respectively, representing growth of 47%, 27%, and 29% compared to 2024, demonstrating increasing market acceptance of the company's product line.
- Significant Net Income Increase: Rigel achieved a net income of $268.1 million in Q4 2025, with earnings per share of $14.72, a substantial rise from $14.3 million and $0.81 in the same quarter of 2024, reflecting a marked improvement in the company's profitability.
- Optimistic 2026 Outlook: Rigel anticipates total revenues of approximately $275 to $290 million for 2026 and plans to advance its R289 program, showcasing the company's confidence and strategic positioning for future growth.
See More
Rigel Pharmaceuticals Q4 Earnings Exceed Expectations
- Strong Earnings Report: Rigel Pharmaceuticals reported a Q4 GAAP EPS of $13.54, surpassing expectations by $12.31, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenues of $69.8 million, reflecting a 21.2% year-over-year increase and exceeding market expectations by $1.1 million, indicating sustained competitiveness of its products in the market.
- Future Outlook: Rigel anticipates total revenues for 2026 to be between $275 million and $290 million, with net product sales projected at $255 million to $265 million and contract revenues at $20 million to $25 million, showcasing confidence in future growth.
- Positive Market Response: Rigel Pharmaceuticals presented its ongoing financial performance and future catalysts at the 44th Annual J.P. Morgan Healthcare Conference, further solidifying its market position in the biopharmaceutical sector.
See More
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Rigel Pharmaceuticals Appoints New Board Member
- New Board Member: Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of commercial and leadership experience in the biotechnology and pharmaceutical industries, which is expected to provide valuable insights for the company's strategic plans.
- Commercial Execution Expertise: Miller previously served as Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and held senior commercial roles at Vivus and Genentech, and his extensive experience will aid Rigel in achieving its goals of growing its drug portfolio and exploring potential in-licensing opportunities.
- Company Growth Outlook: Miller noted that Rigel has evolved into a profitable company with a strong commercial engine capable of funding a promising development pipeline, a significant advantage in the biotechnology space.
- Commitment to Patient Care: Miller expressed excitement about joining Rigel and is committed to focusing on opportunities to serve more patients with hematologic disorders and cancer, underscoring the company's dedication to improving patient lives.
See More
Rigel Pharmaceuticals Projects 2026 Revenue of $275 to $290 Million
- Strong Financial Performance: Rigel Pharmaceuticals anticipates total revenue for 2025 to reach approximately $275 to $290 million, reflecting robust commercial execution and expected positive net income, which will further solidify its financial foundation.
- Significant Clinical Advancements: Rigel's R289 drug has shown promising data in the Phase 1b trial for lower-risk myelodysplastic syndromes (MDS), marking a major milestone in clinical development that could pave the way for future market expansion.
- Robust Cash Flow: In 2025, Rigel successfully generated $77 million in cash, ensuring ample funding for existing and new clinical development programs, thereby enhancing its competitive position in the market.
- Investor Event Arrangement: CEO Raul Rodriguez will present an overview of the company at the J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to further enhance the company's visibility and credibility among investors.
See More
